PB 125 of 2023
National Health (Minimum Stockholding) Amendment Determination (No. 3) 2023
I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.
Dated 30 November 2023
Nikolai Tsyganov
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care
Contents
1 Name
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments
National Health (Minimum Stockholding) Determination 2023
(1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 3) 2023.
(2) This instrument may also be cited as PB 125 of 2023.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 December 2023 | 1 December 2023 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
National Health (Minimum Stockholding) Determination 2023
1 Schedule 1
After:
Acarbose | Tablet 50 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
insert:
Aciclovir | Tablet 200 mg | Oral | GenRx Aciclovir | between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand |
2 Schedule 1
Omit:
Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | Alendronate Plus D3 Sandoz | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
3 Schedule 1
Omit:
Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | Alendronate Plus D3 Sandoz | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
4 Schedule 1
Omit:
Amino acid formula with vitamins and minerals without phenylalanine | Oral gel 85 g, 30 (PKU squeezie)
| Oral
| PKU squeezie
| after 30 November 2023—6 months stock by reference to usual PBS demand |
substitute:
Amino acid formula with vitamins and minerals without phenylalanine | Oral gel 85 g, 30 (PKU squeezie) | Oral | PKU squeezie | 0 months stock by reference to usual PBS demand |
5 Schedule 1
Omit:
Amisulpride | Tablet 400 mg | Oral | Amisulpride 400 Winthrop | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
6 Schedule 1
After:
Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand; (b) after 31 December 2023—4.5 months stock by reference to usual demand |
insert:
Amlodipine | Tablet 10 mg (as besilate) | Oral | Amlodipine Amneal | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Amlodipine | Tablet 5 mg (as besilate) | Oral | Amneal | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Amoxyclav AN 500/125 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | Amoxyclav AN 875/125 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
|
7 Schedule 1
Omit:
Anastrozole | Tablet 1 mg | Oral | Anastrozole FBM | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
8 Schedule 1
Omit:
Aripiprazole | Tablet 10 mg | Oral | Aripiprazole generichealth | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
9 Schedule 1
Omit:
Aripiprazole | Tablet 15 mg | Ora | Aripiprazole generichealth | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
10 Schedule 1
Omit:
Aripiprazole | Tablet 20 mg | Oral | Aripiprazole generichealth | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
11 Schedule 1
After:
Aripiprazole | Tablet 30 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
insert:
Aripiprazole | Tablet 30 mg | Oral | Aripiprazole generichealth | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
12 Schedule 1
After:
Atenolol | Tablet 50 mg | Oral | APX‑Atenolol | 4 months stock by reference to usual demand |
insert:
Atenolol | Tablet 50 mg | Oral | Atenolol Amneal | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
13 Schedule 1
Omit:
Betamethasone | Cream 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
Betamethasone | Cream 500 micrograms (as dipropionate) per g, 15 g | Application | Eleuphrat | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
Betamethasone | Ointment 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
Betamethasone | Ointment 500 micrograms (as dipropionate) per g, 15 g | Application | Eleuphrat | between 1 July 2023 and 30 September 2023—2 months stock by reference to usual demand |
14 Schedule 1
After:
Baclofen | Tablet 10 mg | Oral | APO‑Baclofen | 3 months stock by reference to usual demand |
insert:
Bleomycin | Powder for injection containing bleomycin sulfate 15,000 I.U. | Injection | CIPLA BLEOMYCIN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
15 Schedule 1
After:
Bosentan | Tablet 125 mg (as monohydrate) | Oral | Bosentan APO | 3 months stock by reference to usual demand |
insert:
Bosentan | Tablet 62.5 mg (as monohydrate) | Oral | Bosentan Cipla | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Calcitriol | Capsule 0.25 microgram | Oral | Calcitriol AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
16 Schedule 1
Omit:
Carboplatin | Solution for I.V. injection 450 mg in 45 mL | Injection | DBL Carboplatin | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
17 Schedule 1
After:
Cefalexin | Capsule 500 mg (as monohydrate) | Oral | APO‑Cephalexin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
insert:
Cefazolin | Powder for injection 2 g (as sodium) | Injection | Cefazolin-AFT | between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand |
Cefepime | Powder for injection 1 g (as hydrochloride) | Injection | Cefepime Alphapharm | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
18 Schedule 1
After:
Cefepime | Powder for injection 1 g (as hydrochloride) | Injection | Cefepime‑AFT | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Cefepime | Powder for injection 2 g (as hydrochloride) | Injection | Cefepime Alphapharm | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
19 Schedule 1
Omit:
Cefepime | Powder for injection 2 g (as hydrochloride) | Injection | Cefepime‑AFT | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
20 Schedule 1
After:
Cefepime | Powder for injection 2 g (as hydrochloride) | Injection | Cefepime Alphapharm | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
insert:
Ceftriaxone | Powder for injection 1 g (as sodium) | Injection | Ceftriaxone-AFT | between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand |
Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone-AFT | between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand |
21 Schedule 1
Omit:
Chlorpromazine | Tablet containing chlorpromazine hydrochloride 10 mg | Oral | Largactil | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
22 Schedule 1
After:
Ciclosporin | Oral liquid 100 mg per mL, 50 mL | Oral | Neoral | 4 months stock by reference to usual PBS demand |
insert:
Citalopram | Tablet 10 mg (as hydrobromide) | Oral | Citalopram AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | Citalopram AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Citalopram | Tablet 40 mg (as hydrobromide) | Oral | Citalopram AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
23 Schedule 1
After:
Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL | Oral | Klacid | 4 months stock by reference to usual PBS demand |
insert:
Clarithromycin | Tablet 250 mg | Oral | Clarithromycin AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
24 Schedule 1
Omit:
Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)‑100 mg | Oral | CLOPIDOGREL/ASPIRIN AN 75/100 | between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand |
25 Schedule 1
After:
Cyproterone | Tablet containing cyproterone acetate 100 mg | Oral | APO‑Cyproterone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Cyproterone | Tablet containing cyproterone acetate 100 mg | Oral | Cyprone 100 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
26 Schedule 1
After:
Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | APO‑Cyproterone | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | Cyprone 50 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
27 Schedule 1
Omit:
Desferrioxamine | Powder for injection containing desferrioxamine mesilate 2 g | Injection | DBL Desferrioxamine Mesilate | between 1 July 2023 and 31 July 2023—4 months stock by reference to usual demand |
28 Schedule 1
After:
Dantrolene | Capsule containing dantrolene sodium hemiheptahydrate 25 mg | Oral | Dantrium | 6 months stock by reference to usual PBS demand |
insert:
Desvenlafaxine | Tablet (modified release) 100 mg | Oral | Desvenlafaxine Actavis | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Desvenlafaxine | Tablet (modified release) 50 mg | Oral | Desvenlafaxine Actavis | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
29 Schedule 1
After:
Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral | Diazepam Elixir | 4 months stock by reference to usual PBS demand |
insert:
Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | Diclofenac AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
30 Schedule 1
After:
Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | Diclofenac Sandoz | between 1 November 2023 and 30 April 2024—4 months stock by reference to usual demand |
insert:
Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | Diclofenac AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
31 Schedule 1
After:
Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | Fenac | (a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand; (b) after 31 December 2023—2 months stock by reference to usual demand |
insert:
Diltiazem | Tablet containing diltiazem hydrochloride 60 mg | Oral | Diltiazem AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
32 Schedule 1
After:
Domperidone | Tablet 10 mg | Oral | Motilium | between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand |
insert:
Dosulepin | Tablet containing dosulepin hydrochloride 75 mg | Oral | Dosulepin Viatris 75 | 6 months stock by reference to usual demand of both Dosulepin Viatris 75 and Dosulepin Mylan added together |
33 Schedule 1
Omit:
Entecavir | Tablet 1 mg (as monohydrate) | Oral | ENTAC | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
Entecavir | Tablet 1 mg (as monohydrate) | Oral | Entecavir GH | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
34 Schedule 1
After:
Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
insert:
Ezetimibe with simvastatin | Tablet 10 mg-10 mg | Oral | EZEVYT 10/10 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
35 Schedule 1
After:
Ezetimibe with simvastatin | Tablet 10 mg‑20 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
insert:
Ezetimibe with simvastatin | Tablet 10 mg-20 mg | Oral | EZEVYT 10/20 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
36 Schedule 1
After:
Ezetimibe with simvastatin | Tablet 10 mg‑40 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
insert:
Ezetimibe with simvastatin | Tablet 10 mg-40 mg | Oral | EZEVYT 10/40 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
37 Schedule 1
After:
Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | EZETORIN | 3 months stock by reference to usual demand |
insert:
Ezetimibe with simvastatin | Tablet 10 mg-80 mg | Oral | EZEVYT 10/80 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
38 Schedule 1
After:
Ezetimibe with simvastatin | Tablet 10 mg‑80 mg | Oral | Zeklen 10/80 mg | between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand |
insert:
Famciclovir | Tablet 125 mg | Oral | Famciclovir-GA | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Famciclovir | Tablet 250 mg | Oral | Famciclovir-GA | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Famciclovir | Tablet 500 mg | Oral | Famciclovir-GA | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
39 Schedule 1
After:
Felodipine | Tablet 2.5 mg (extended release) | Oral | Plendil ER | 2.5 months stock by reference to usual demand |
insert:
Fenofibrate | Tablet 145 mg | Oral | Fenofibrate Viatris | 6 months stock by reference to usual demand of both Fenofibrate Viatris and Fenofibrate Mylan added together |
40 Schedule 1
Omit:
Filgrastim | Injection 300 micrograms in 0.5 mL single‑use pre‑filled syringe | Injection | Neupogen | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
Filgrastim | Injection 300 micrograms in 1 mL | Injection | Neupogen | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand
|
Filgrastim | Injection 480 micrograms in 0.5 mL single‑use pre‑filled syringe | Injection | Neupogen | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
Filgrastim | Injection 480 micrograms in 1.6 mL | Injection | Neupogen | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
41 Schedule 1
Omit:
Flucloxacillin | Powder for injection 1 g (as sodium monohydrate)
| Injection | Flucil | between 1 July 2023 and 30 November 2023—4 months stock by reference to usual demand |
Flucloxacillin | Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL | Oral | Flucil | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
Flucloxacillin | Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL | Oral | Flucil | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
42 Schedule 1
Omit:
Fluorouracil | Injection 2500 mg in 50 mL | Injection | DBL Fluorouracil Injection BP | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Blooms the Chemist Fluoxetine | between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand |
43 Schedule 1
After:
Furosemide | Oral solution 10 mg per mL, 30 mL | Oral | Lasix | 4 months stock by reference to usual PBS demand |
insert:
Furosemide | Tablet 20 mg | Oral | FUROSEMIDE AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
44 Schedule 1
After:
Furosemide | Tablet 20 mg | Oral | Urex‑M | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Furosemide | Tablet 40 mg | Oral | FUROSEMIDE AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
45 Schedule 1
After:
Gabapentin | Capsule 400 mg | Oral | GAPENTIN | 3 months stock by reference to usual demand |
insert:
Gabapentin | Tablet 600 mg | Oral | Gabapentin AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
46 Schedule 1
After:
Gemfibrozil | Tablet 600 mg | Oral | Lipigem | between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand |
insert:
Glimepiride | Tablet 2 mg | Oral | Amaryl | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
47 Schedule 1
Omit:
Glimepiride | Tablet 4 mg | Oral | Amaryl | between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand |
48 Schedule 1
Omit:
Glucose indicator‑urine | Test strips, 50 (Diastix) | For External Use | Diastix | 4 months stock by reference to usual PBS demand |
substitute:
Glucose indicator-urine | Test strips, 50 (Diastix) | For External Use | Diastix | between 1 December 2023 and 29 February 2024—0 months stock by reference to usual demand |
49 Schedule 1
Omit:
Hydralazine | Tablet containing hydralazine hydrochloride 25 mg | Oral | Alphapress 25 | 4 months stock by reference to usual PBS demand |
substitute:
Hydralazine | Tablet containing hydralazine hydrochloride 25 mg | Oral | Alphapress 25 | between 1 December 2023 and 31 March 2024—0 months stock by reference to usual PBS demand |
50 Schedule 1
After:
Hydralazine | Tablet containing hydralazine hydrochloride 25 mg | Oral | Alphapress 25 | between 1 December 2023 and 31 March 2024—0 months stock by reference to usual PBS demand |
insert:
Hydrocortisone | Tablet 20 mg | Oral | Hydrocortisone Viatris 20 | 4 months stock by reference to usual demand of both Hydrocortisone Viatris 20 and Hydrocortisone Mylan 20 added together |
51 Schedule 1
Omit:
Imatinib | Capsule 100 mg (as mesilate) | Oral | CIPLA IMATINIB ADULT | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib GH | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
52 Schedule 1
Omit:
Imatinib | Capsule 400 mg (as mesilate) | Oral | CIPLA IMATINIB ADULT | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
53 Schedule 1
Omit:
Insulin glargine | Injections (human analogue), cartridge, 300 units per mL, 1.5 mL, 3 | Injection | Toujeo Solostar | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
Insulin glargine | Injections (human analogue), cartridges, 300 units per mL, 1.5 mL, 5 | Injection | Toujeo Solostar | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand
|
54 Schedule 1
After:
Irbesartan with hydrochlorothiazide | Tablet 300 mg‑25 mg | Oral | AVSARTAN HCT 300/25 | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
insert:
Irbesartan | Tablet 300 mg | Oral | Irbesartan AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Irbesartan | Tablet 75 mg | Oral | Irbesartan AMNEAL | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Irbesartan | Tablet 75 mg | Oral | Irbesartan AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Irinotecan | I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL | Injection | MEDITAB IRINOTECAN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Irinotecan | I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL | Injection | MEDITAB IRINOTECAN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Isosorbide mononitrate | Tablet 60 mg (sustained release) | Oral | Isosorbide AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Isosorbide mononitrate | Tablet 60 mg (sustained release) | Oral | Monodur 60 mg | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Isotretinoin | Capsule 10 mg | Oral | Rocta 10 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Isotretinoin | Capsule 20 mg | Oral | Rocta 20 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
55 Schedule 1
Omit:
Labetalol | Tablet containing labetalol hydrochloride 200 mg | Oral | Trandate | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
56 Schedule 1
Omit:
Letrozole | Tablet 2.5 mg | Oral | Letrozole FBM | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
57 Schedule 1
Omit:
Losartan | Tablet containing losartan potassium 25 mg | Oral | Cozavan | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
Macrogol 3350 | Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL | Oral | Movicol Liquid | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
58 Schedule 1
After:
Macrogol 3350 | Powder for oral solution 510 g | Oral | OsmoLax | between 1 November 2023 and 31 March 2024—4 months stock by reference to usual demand |
insert:
Meloxicam | Capsule 15 mg | Oral | Chem mart Meloxicam | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Meloxicam | Capsule 15 mg | Oral | Terry White Chemists Meloxicam | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Meloxicam | Capsule 7.5 mg | Oral | Chem mart Meloxicam | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Meloxicam | Capsule 7.5 mg | Oral | Terry White Chemists Meloxicam | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
59 Schedule 1
After:
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | APO‑Metformin 1000 | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Metformin AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
|
60 Schedule 1
After:
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | APO‑Metformin 500 | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | Metformin AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
|
61 Schedule 1
After:
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | APO‑Metformin 850 | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Chem mart Metformin | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Metformin AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Terry White Chemists Metformin | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
62 Schedule 1
Omit:
Methotrexate | Injection 50 mg in 2 mL vial | Injection | Methotrexate Accord | between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand |
63 Schedule 1
After:
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Terry White Chemists Metformin | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
insert:
Methotrexate | Solution concentrate for I.V. infusion 1000 mg in 10 mL vial | Injection | Pfizer Australia Pty Ltd | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
64 Schedule 1
After:
Methoxyflurane | Liquid for inhalation 999 mg per g, 3 ml (with inhaler) | Inhalation by mouth | Penthrox | 6 months stock by reference to usual PBS demand |
insert:
Metoclopramide | Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL | Injection | Maxolon | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
65 Schedule 1
After:
Metoprolol | Tablet containing metoprolol tartrate 50 mg | Oral | Metrol 50 | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |
insert:
Mirtazapine | Tablet 15 mg (orally disintegrating) | Oral | Mirtazapine AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
66 Schedule 1
After:
Mirtazapine | Tablet 15 mg | Oral | APO‑Mirtazapine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Mirtazapine | Tablet 30 mg (orally disintegrating) | Oral | Mirtazapine AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
67 Schedule 1
After:
Mirtazapine | Tablet 30 mg | Oral | APO‑Mirtazapine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Mirtazapine | Tablet 30 mg | Oral | Mirtazon | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Mirtazapine | Tablet 45 mg (orally disintegrating) | Oral | Mirtazapine AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
68 Schedule 1
After:
Mirtazapine | Tablet 45 mg | Oral | APO‑Mirtazapine | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Mirtazapine | Tablet 45 mg | Oral | Mirtazon | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Mitozantrone | Injection 20 mg (as hydrochloride) in 10 mL | Injection | Onkotrone | between 1 December 2023 and 29 February 2024—0 months stock by reference to usual demand |
Mitozantrone | Injection 25 mg (as hydrochloride) in 12.5 mL | Injection | Onkotrone | between 1 December 2023 and 29 February 2024—0 months stock by reference to usual demand |
69 Schedule 1
After:
Moclobemide | Tablet 150 mg | Oral | APO‑Moclobemide | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Moclobemide | Tablet 150 mg | Oral | Moclobemide AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
70 Schedule 1
After:
Moclobemide | Tablet 300 mg | Oral | APO‑Moclobemide | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Moclobemide | Tablet 300 mg | Oral | Moclobemide AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
71 Schedule 1
After:
Morphine | Tablet containing morphine sulfate pentahydrate 30 mg | Oral | Anamorph | 3 months stock by reference to usual demand |
insert:
Moxonidine | Tablet 200 micrograms | Oral | Moxonidine Viatris | 4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together |
72 Schedule 1
Omit:
Mycophenolic Acid | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL | Oral | CellCept | between 1 July 2023 and 30 September 2023—4 months stock by reference to usual PBS demand |
73 Schedule 1
Omit:
Nicorandil | Tablets 10 mg, 60 | Oral | Ikorel | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
74 Schedule 1
Omit:
Nicorandil | Tablets 20 mg, 60 | Oral | Ikorel | between 1 July 2023 and 30 November 2023—0 months stock by reference to usual demand |
75 Schedule 1
After:
Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | APO‑Ondansetron ODT | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | Ondansetron AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
76 Schedule 1
Omit:
Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | Ondansetron ODT Lupin | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
77 Schedule 1
After:
Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | APO‑Ondansetron ODT | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | Ondansetron AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
78 Schedule 1
Omit:
Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | Ondansetron ODT Lupin | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
79 Schedule 1
After:
Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | Ondansetron AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
insert:
Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | Ondansetron AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
80 Schedule 1
After:
Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | Ondansetron APOTEX | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Ondansetron | Tablet 8 mg (as hydrochloride dihydrate) | Oral | Ondansetron AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
81 Schedule 1
Omit:
Oxaliplatin | Solution concentrate for I.V. infusion 100 mg in 20 mL | Injection | DBL Oxaliplatin Concentrate | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
82 Schedule 1
After:
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Sozol | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |
insert:
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
83 Schedule 1
Omit:
Paracetamol | Tablet 665 mg (modified release) | Oral | CHEMISTS' OWN OSTEO RELIEF PARACETAMOL | between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand |
84 Schedule 1
After:
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand; (b) after 31 December 2023—5.5 months stock by reference to usual demand |
insert:
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Paroxetine AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Pegfilgrastim | Injection 6 mg in 0.6 mL single use pre-filled syringe | Injection | Ristempa | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
85 Schedule 1
Omit:
Pemetrexed | Powder for I.V. infusion 100 mg (as disodium) | Injection | Pemetrexed‑AFT | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
Pemetrexed | Powder for I.V. infusion 500 mg (as disodium) | Injection | Pemetrexed‑AFT | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
86 Schedule 1
Omit:
Polyvinyl alcohol | Eye drops 14 mg per mL, 15 mL | Application to the Eye | Liquifilm Tears | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
Polyvinyl alcohol | Eye drops 14 mg per mL, 15 mL | Application to the Eye | PVA Tears | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |
87 Schedule 1
After:
Pregabalin | Capsule 25 mg | Oral | LYPRALIN | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Pregabalin | Capsule 25 mg | Oral | Pregabalin Lupin | 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together |
88 Schedule 1
After:
Pregabalin | Capsule 300 mg | Oral | LYPRALIN | between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand |
insert:
Pregabalin | Capsule 300 mg | Oral | Pregabalin Lupin | 4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together |
89 Schedule 1
After:
Probenecid | Tablet 500 mg | Oral | Pro‑Cid | after 30 November 2023—6 months stock by reference to usual PBS demand |
insert:
Quetiapine | Tablet 100 mg (as fumarate) | Oral | Quetiapine AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Quetiapine | Tablet 300 mg (as fumarate) | Oral | Quetiapine AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
90 Schedule 1
After:
Ramipril with felodipine | Tablet 2.5 mg‑2.5 mg (modified release) | Oral | Triasyn 2.5/2.5 | 4 months stock by reference to usual PBS demand |
insert:
Ramipril | Capsule 1.25 mg | Oral | APO-Ramipril | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
91 Schedule 1
Omit:
Ranitidine | Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL | Oral | Zantac Syrup | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual PBS demand |
92 Schedule 1
After:
Risperidone | Tablet 4 mg | Oral | Rispa | between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand |
insert:
Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral | Rizatriptan AN ODT | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
93 Schedule 1
Omit:
Roxithromycin | Tablet for oral suspension 50 mg | Oral | Rulide D | between 1 July 2023 and 31 July 2023—0 months stock by reference to usual demand |
94 Schedule 1
After:
Roxithromycin | Tablet 300 mg | Oral | APX‑Roxithromycin | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand; (b) after 31 December 2023—5 months stock by reference to usual demand |
insert:
Salbutamol | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 | Inhalation | Salbutamol AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Sertraline AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Sertraline AN | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
Sildenafil | Tablet 20 mg (as citrate) | Oral | Sildenafil AN PHT 20 | between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand |
95 Schedule 1
Omit:
Telmisartan with hydrochlorothiazide | Tablet 80 mg‑25 mg | Oral | Telmisartan HCT GH 80/25 | between 1 July 2023 and 30 September 2023—0 months stock by reference to usual demand |
96 Schedule 1
Omit:
Tobramycin | Injection 80 mg in 2 mL | Injection | DBL Tobramycin | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
97 Schedule 1
Omit:
Triglycerides - medium chain, formula | Oral powder 400 g (Lipistart) | Oral | Lipistart | after 30 November 2023—6 months stock by reference to usual PBS demand |
substitute:
Triglycerides—medium chain, formula | Oral powder 400 g (Lipistart) | Oral | Lipistart | 0 months stock by reference to usual PBS demand |
98 Schedule 1
Omit:
Triglycerides, medium chain | Oral liquid 225 mL, 15 (K.Quik) | Oral | K.Quik | after 30 November 2023—6 months stock by reference to usual PBS demand |
substitute:
Triglycerides, medium chain | Oral liquid 225 mL, 15 (K.Quik) | Oral | K.Quik | 0 months stock by reference to usual PBS demand |
99 Schedule 1
After:
Valganciclovir | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL | Oral | Valcyte | 4 months stock by reference to usual PBS demand |
insert:
Valganciclovir | Tablet 450 mg (as hydrochloride) | Oral | Valganciclovir Viatris | 4 months stock by reference to usual demand of both Valganciclovir Viatris and Valganciclovir Mylan added together |
100 Schedule 1
Omit:
Vancomycin | Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
101 Schedule 1
Omit:
Voriconazole | Tablet 50 mg | Oral | Vfend | between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |